Platelet Function in Hyperbetalipoproteinemia^[*]

Summary

Individuals with familial hyperbetalipoproteinemia are at increased risk of premature atherosclerosis and thrombosis. Although there is controversy whether platelet survival is shortened or normal in this disease, several in vitro tests of platelet function are abnormal including a decreased threshold concentration for stimulation of aggregation by ADP, epinephrine and collagen and increased release of nucleotides to the same agents. These functional changes are accompanied by an increase of cholesterol to phospholipid ratio in the platelet membrane and in low density lipoprotein in individuals with type Ha hyperlipoproteinemia. Clofibrate and halofenate reverse some of the abnormalities in vitro and the former drug, when administered for 6 weeks to patients with type II a hyperlipoproteinemia decreases platelet sensitivity to ADP and epinephrine. The platelet hypersensitivity to aggregating agents can be reproduced in vitro by increasing the cholesterol to phospholipid rather in normal platelets. These artificially hypersensitive platelets can be returned to normal by halofenate in vitro. Incorporation of cholesterol into platelet membranes increases the basal level of the membrane associated enzyme adenylate cyclase. However, the enzyme no longer responds to stimulation by prostaglandin E₁ and this is associated with relative resistance of the platelet to inhibition by this pharmacologic agent. These functional alterations produced by cholesterol enrichment of platelet membranes occur is parallel with an increase in platelet membrane microviscosity suggesting that the more rigid membrane can alter the behavior of membrane associated enzymes and receptors. A correlation appears to exist between the ability of certain drugs to induce phase separation in model membranes and the potency in inhibitory platelet aggregation.

^* Presented at the VIth International Congress on Thrombosis and Haemostasis, Philadelphia, USA

• References

• 1 Carvalho ACA, Colman RW, Lees RS. 1974; a Platelet Function in Hyperbetalipo-proteinemia. The New England Journal of Medicine 290: 434
• 2 Carvalho ACA, Colman RW, Lees RS. 1974; Clofibrate Reversal of Platelet Hypersensitivity in Hyperbetalipoproteinemia. Circulation 50: 570
• 3 Colman RW, Bennett JS, Sheridan JF, Cooper RA, Shattil SJ. 1976; Halofenate: A Potent Inhibitor of Normal and Hypersensitive Platelets. The Journal of Laboratory and Clinical Medicine 88: 282
• 4 Colman RW, Kuchibholta J, Jain MK, Murray Jr RK. 1977; Phase Separation in Lecithinbilayers as a Prediction of Inhibition of Blood Platelet Aggregation by Amantadines. Biochimica et biophysica acta 467: 273
• 5 Cooper RA, Arner EC, Wiley JS, Shattil SJ. 1975; Modification of Red Cell Membrane Structure by Cholesterol-rich Lipid Dispersions. A Model for the Primary Spur Cell Defect. The Journal of Clinical Investigation 55: 115
• 6 French JE. 1971; Athrogenesis And Thrombosis. Seminars in Hematology 8: 84
• 7 Kannel WB, Castelli WP, McNamara PM. 1967; The Coronary Profile: 12-Year Follow-up in the Framingham Study. The Journal of Occupational Medicine 9: 611
• 8 Mielke CH. 1977. Personal Communication.
• 9 Shattil SJ, Bennett JS, Colman RW, Cooper RA. 1977; Abnormalities of Cholesterol-Phospholipid Composition in Platelets and Low-Density Lipoproteins of Human Hyperbetalipo-proteinemia. The Journal of Laboratory and Clinical Medicine 89: 341
• 10 Shattil SJ, Cooper RA. 1976; Membrane Microviscosity and Human Platelet Function. Biochemistry 15: 4832
• 11 Sinha AK, Shattil SJ, Colman RW. 1977; Cyclic AMP Metabolism in Cholesterol-rich Platelets. The Journal of Biological Chemistry 252: 3310